Exodus Point Capital Management, LP Morpho Sys Ag Transaction History

Exodus Point Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$17.36 - $19.34 $1.4 Million - $1.56 Million	-80,663 Reduced 99.43%	465 $8,000
Q1 2024 May 14, 2024	SELL	$8.6 - $18.18 $1.5 Million - $3.17 Million	-174,436 Reduced 68.26%	81,128 $1.47 Million
Q3 2023 Nov 09, 2023	BUY	$6.72 - $8.6 $1.72 Million - $2.2 Million	255,564 New	255,564 $1.72 Million
Q2 2022 Aug 19, 2022	SELL	$4.51 - $7.39 $47,616 - $78,023	-10,558 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.87 - $9.73 $950 - $1,576	-162 Reduced 1.51%	10,558 $72,000
Q4 2021 Feb 11, 2022	BUY	$9.08 - $12.45 $97,337 - $133,464	10,720 New	10,720 $101,000

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.